BioCentury | Sep 30, 2020
Product Development

Partner Amgen becomes investor as Carmot pushes diabetes therapies ahead with $47M series C

Amgen has joined the syndicate of investors backing Carmot in a $47 million series C round that will advance its lead Type II diabetes candidate — a therapy developed using the same platform that spawned...
BioCentury | Nov 19, 2019

Reducing ER stress through USP14 inhibition could treat diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes Targeting USP14 could treat Type II diabetes by reducing the effects of endoplasmic reticulum stress, which has been implicated in the disease’s pathogenesis. In lean mice, the ER stress inducer...
BioCentury | Feb 22, 2019
Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
BioCentury | May 11, 2018
Company News

Forma, Oxford in deubiquitinating enzyme inhibitor deal

Forma Therapeutics Inc. (Watertown, Mass.) and University of Oxford (Oxford, U.K.) partnered to identify and develop deubiquitinating enzyme (DUB) inhibitors to treat neurodegenerative diseases. Forma will provide undisclosed funding to the university for a research...
BioCentury | Feb 8, 2018

External rethink

As the industry seeks to develop new ways to access external innovation, companies are re-evaluating the value of public-private partnerships, and increasingly turning to other companies for research partnerships in lieu of broad deals with...
BioCentury | Jan 3, 2018
Preclinical News

CYLD expression could slow progression of NASH

In a paper published in Nature Medicine , researchers at Wuhan University and Weill Cornell Medicine found that increasing expression of the deubiquitinating enzyme cylindromatosis turban tumor syndrome (CYLD) reversed progression of non-alcoholic steatohepatitis (NASH) in...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BioCentury | Nov 2, 2017
Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...
BioCentury | Oct 10, 2017
Distillery Therapeutics


INDICATION: Acute myelogenous leukemia (AML) In vitro , cell culture and mouse studies identified two USP10 inhibitors that could help treat AML harboring internal tandem duplication (ITD) mutations in FLT3 . Screening of deubiquitinating enzyme (DUB) inhibitors...
BioCentury | Oct 5, 2017
Preclinical News

FLT3 degradation via USP10 could treat AML

In a paper published in Nature Chemical Biology , researchers at Dana-Farber Cancer Institute and colleagues identified ubiquitin specific peptidase 10 (USP10), a deubiquitinating enzyme (DUB), as a target to degrade FMS-like tyrosine kinase 3 ( FLT3...
Items per page:
1 - 10 of 36